Rudin, C. M., Cervantes, A., Dowlati, A., Besse, B., Ma, B., Costa, D. B., . . . Gettinger, S. (2023). Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer.
Citación estilo ChicagoRudin, C M., et al. Safety and Clinical Activity of Atezolizumab Plus Erlotinib in Patients With Non-small-cell Lung Cancer. 2023.
Cita MLARudin, C M., et al. Safety and Clinical Activity of Atezolizumab Plus Erlotinib in Patients With Non-small-cell Lung Cancer. 2023.
Precaución: Estas citas no son 100% exactas.